Chemo-immunotherapy plus radiation before breast cancer surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for a certain type of breast cancer (hormone receptor-positive, HER2-negative, with fast-growing cells). The goal is to see if this combination shrinks tumors more effectively before removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with breast cancer and have not started treatment.
- You are between 18 and 75 years old.
- Your cancer cells have hormone receptors (ER positive) and are not HER2 positive (HER2 0/1+ or 2+ with negative FISH).
- Your cancer has a high growth rate (Ki67 score of 20% or higher).
- Your tumor is at least 2 cm (about 0.8 inches) and may have spread to lymph nodes nearby.
- You have good lung and organ function and a performance status of 0 or 1 (fully active or slightly restricted).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy, an immunotherapy drug (PD-1 inhibitor), and different types of radiation before surgery for people with a common type of breast cancer (HR+/HER2-). The goal is to see which radiation plan works best to shrink tumors.
This trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery helps women with a certain type of breast cancer (HR+, HER2-). It aims to see if this combination works better than chemotherapy alone.
This trial tests combining two treatments—an immunotherapy drug (Toripalimab) and radiation—before surgery for a certain type of breast cancer (HR+, HER2-negative) that has spread to lymph nodes. The goal is to see if this combination helps shrink the tumor more than standard therapy alone.
This trial tests adding radiation therapy to chemotherapy before surgery for people with locally advanced breast cancer that did not shrink enough with chemo alone. It may help improve outcomes for those with luminal (HER2-negative) or triple-negative types.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Hear when a new HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.